Synlogic Inc. (SYBX) stock was trading up 4.88% in premarket trading at $4.30 as of the last check. Synlogic stock closed yesterday at $4.10, rising 4.59% or $0.18. SYBX stock traded between $3.96 and $4.29 yesterday.

There were 380.5K shares exchanged in SYBX stock, less than the 0.45 million daily volume average of the company over the last 50 days and less than its 0.82 million volume year-to-date. Incorporating a research partnership for the development of new therapies has increased SYBX stock prices.

In what therapy is SYBX engaged?

With Synlogic, the potential of synthetic biology in medicine is unleashed. SYBX develops synthetic biologics of the highest quality that are based on reproducible, modular approaches to microbial engineering that target validated biological principles. The Synthetic Biotics pipeline of SYBX includes products designed to treat metabolic disorders like Phenylketonuria (PKU) and enteric hyperoxia.

Synlogic It has been announced today that Synlogic is collaborating with Roche on the development of new therapies..

• The collaboration between SYBX and Roche is to find a new Synthetic Biotic medicine for the treatment of inflammatory bowel disease (IBD).
• A Synthetic Biotic Medicine addressing undisclosed novel targets in IBD will be developed through collaboration between SYBX and Roche.
• Roche will be able to explore the potential of a new treatment modality for IBD through its collaboration with SYBX.
• As the conclusion of the research period approaches, Roche will have the exclusive option of entering into a licensing and collaboration agreement with SYBX for further commercialization and development of the program.

How will both firms collaborate?

In addition to advancing innovative science, both Synlogic (SYBX) and Roche provide breakthrough medicines to patients with inflammatory diseases. This collaboration will allow SYBX to develop Synthetic Biotic medicines that are beneficial to patients, as well as expand those efforts into inflammation, which will also address the unmet needs for patients diagnosed with inflammatory bowel disease.